Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Cash Flow (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Net Cash Flow for 13 consecutive years, with -$96.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 26.94% to -$96.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.8 million, a 1834.78% increase, with the full-year FY2025 number at $98.8 million, up 1834.78% from a year prior.
  • Net Cash Flow was -$96.9 million for Q4 2025 at Madrigal Pharmaceuticals, down from $109.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $522.6 million in Q1 2024 to a low of -$261.9 million in Q3 2024.
  • A 5-year average of $7.5 million and a median of -$3.6 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: surged 2209.33% in 2022, then crashed 3729.49% in 2023.
  • Madrigal Pharmaceuticals' Net Cash Flow stood at -$12.9 million in 2021, then soared by 2209.33% to $272.2 million in 2022, then crashed by 86.09% to $37.9 million in 2023, then tumbled by 450.41% to -$132.7 million in 2024, then rose by 26.94% to -$96.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Net Cash Flow are -$96.9 million (Q4 2025), $109.5 million (Q3 2025), and $2.5 million (Q2 2025).